Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells

Alessandrini, 2015, The activation of M2 muscarinic receptor inhibits cell growth and survival in human glioblastoma cancer stem cells, Int. Immunopharm., 29, 105, 10.1016/j.intimp.2015.05.032 Al-Hajj, 2003, Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U. S. A., 100, 3983, 10.1073/pnas.0530291100 Antony, 2009, Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity, FASEB J., 23, 442, 10.1096/fj.08-114751 Barocelli, 2000, New analogues of oxotremorine and oxotremorine-M. Estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes, Life Sci., 67, 717, 10.1016/S0024-3205(00)00661-5 Birdsall, 2005, Allosterism at muscarinic receptors: ligands and mechanisms, Mini Rev. Med. Chem., 5, 523, 10.2174/1389557054023251 Bock, 2012, The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling, Nat. Commun., 3, 1044, 10.1038/ncomms2028 Bock, 2013, Dualsteric GPCR targeting and functional selectivity: the paradigmatic M2 muscarinic acetylcholine receptor, Drug Discov. Today Technol., 10, e245, 10.1016/j.ddtec.2012.12.003 Bock, 2014, Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor, Nat. Chem. Biol., 10, 18, 10.1038/nchembio.1384 Bock, 2016, Ligand binding ensembles determine graded agonist efficacies at a G protein-coupled receptor, J. Biol. Chem., 291, 16375, 10.1074/jbc.M116.735431 Bock, 2017, Allosteric modulators targeting CNS muscarinic receptors, Neuropharmacol Broadley, 2002, Muscarinic receptor agonists and antagonists, Rec. Res. Dev. Org. Chem., 6, 747 Campoy, 2016, Cholinergic system and cell proliferation, Chem. Biol. Inter., 259, 257, 10.1016/j.cbi.2016.04.014 Chilmonczyk, 2014, Ligand-directed trafficking of receptor stimulus, Pharmacol. Rep., 66, 1011, 10.1016/j.pharep.2014.06.006 Conn, 2009, Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders, Trends Pharmacol. Sci., 30, 148, 10.1016/j.tips.2008.12.002 Conti, 2012, REST controls self-renewal and tumorigenic competence of human glioblastoma cells, PLoS One, 7, 10.1371/journal.pone.0038486 Dale, 2014, The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder disease, Curr. Opin. Pharmacol., 16, 31, 10.1016/j.coph.2014.03.003 Dallanoce, 1999, Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M, Bioorg. Med. Chem., 7, 1539, 10.1016/S0968-0896(99)00107-8 De Amici, 2010, Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities, Med. Res. Rev., 30, 463, 10.1002/med.20166 De Min, 2017, A new molecular mechanism to engineer protean agonism at a G protein-coupled receptor, Mol. Pharmacol., 91, 348, 10.1124/mol.116.107276 Di Bari, 2015, E. Cytotoxic and genotoxic effects mediated by M2 muscarinic receptor activation in human glioblastoma cells, Neurochem. Int., 90, 261, 10.1016/j.neuint.2015.09.008 Disingrini, 2006, Design, synthesis and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors, J. Med. Chem., 49, 366, 10.1021/jm050769s Eglen, 2005, Muscarinic receptor subtype pharmacology and physiology, Prog. Med. Chem., 43, 105, 10.1016/S0079-6468(05)43004-0 Ferretti, 2012, M2 muscarinic receptor inhibits cell proliferation in human glioblastoma cell lines, Life Sci., 91, 1134, 10.1016/j.lfs.2012.04.033 Ferretti, 2013, M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells, J. Cell Mol. Med., 17, 552, 10.1111/jcmm.12038 Fish, 2017, Structure-based design and discovery of new M2 receptor agonists, J. Med. Chem., 60, 9239, 10.1021/acs.jmedchem.7b01113 Fredriksson, 2003, The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints, Mol. Pharmacol., 63, 1256, 10.1124/mol.63.6.1256 Holland, 2001, Progenitor cells and glioma formation, Curr. Opin. Neurol., 14, 683, 10.1097/00019052-200112000-00002 Jakubík, 1997, Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors, Mol. Pharmacol., 52, 172, 10.1124/mol.52.1.172 Kebig, 2009, An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators, J. Recept. Signal Transduct. Res., 29, 140, 10.1080/10799890903047437 Kruse, 2013, Muscarinic receptors as model targets and antitargets for structure-based ligand discovery, Mol. Pharmacol., 84, 528, 10.1124/mol.113.087551 Levey, 1996, Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 93, 13541, 10.1073/pnas.93.24.13541 Lindsley, 2016, Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors, Chem. Rev., 116, 6707, 10.1021/acs.chemrev.5b00656 Liu, 2015, Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways, Biochem. J., 470, 155, 10.1042/BJ20150358 Matera, 2014, Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity, Eur. J. Med. Chem., 75, 222, 10.1016/j.ejmech.2014.01.032 Matera, 2014, Pharmacological approaches to targeting muscarinic acetylcholine receptors, Recent Pat. CNS Drug Discov., 9, 85, 10.2174/1574889809666141120131238 Mohr, 2010, Rational design of dualsteric GPCR ligands: quests and promise, Br. J. Pharmacol., 159, 997, 10.1111/j.1476-5381.2009.00601.x Mossman, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Meth., 65, 55, 10.1016/0022-1759(83)90303-4 Pacini, 2014, M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells, Canc. Biol. Ther., 15, 1489, 10.4161/15384047.2014.955740 Prilla, 2006, Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity, Mol. Pharmacol., 70, 181, 10.1124/mol.106.023481 Riccardi, 2006, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat. Protoc., 1, 1458, 10.1038/nprot.2006.238 Rispoli, 2014, Neural stem cells and glioblastoma, NeuroRadiol. J., 27, 169, 10.15274/NRJ-2014-10028 Shah, 2009, Muscarinic receptors and ligands in cancer, Am. J. Physiol. Cell Physiol., 296, C221, 10.1152/ajpcell.00514.2008 Shih, 2004, Developmental neurobiology and the origin of brain tumors, J. Neuro Oncol., 70, 125, 10.1007/s11060-004-2746-3 Schrage, 2013, Agonist with supraphysiological efficacy at the muscarinic M2 acetylcholine receptor, Br. J. Pharmacol., 169, 357, 10.1111/bph.12003 Shrage, 2017, Functional selectivity and dualsteric/bitopic GPCR targeting, Curr. Opin. Pharmacol., 32, 85, 10.1016/j.coph.2016.12.001 Shirey, 2008, An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission, Nat. Chem. Biol., 4, 42, 10.1038/nchembio.2007.55 Song, 2007, M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion, Canc. Res., 67, 3936, 10.1158/0008-5472.CAN-06-2484 Tata, 1995, Muscarinic cholinergic receptors in dorsal root ganglia of chick embryos: a radioligand binding and immunocytochemical study, Neurosci. Lett., 189, 139, 10.1016/0304-3940(95)11474-B Tata, 2000, Muscarinic receptor subtypes expression in rat and chick dorsal root ganglia, Mol. Brain Res., 82, 1, 10.1016/S0169-328X(00)00165-0 Urban, 2007, Functional selectivity and classical concepts of quantitative pharmacology, Pharmacol. Exp. Ther., 320, 1, 10.1124/jpet.106.104463 Urwyler, 2011, Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives, Pharmacol. Rev., 63, 59, 10.1124/pr.109.002501 Vescovi, 2006, Brain tumour stem cells, Nat. Rev. Canc., 6, 425, 10.1038/nrc1889 Wess, 2004, Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications, Annu. Rev. Pharmacol. Toxicol., 44, 423, 10.1146/annurev.pharmtox.44.101802.121622 Wess, 2007, Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development, Nat. Rev. Drug Discov., 6, 721, 10.1038/nrd2379